Monte Rosa Therapeutics, Inc.
GLUE evidence brief
What we can confirm
- BioSniper Score:
- 4.7 / 10
- Market Cap:
- $1.22B
- Lead Asset:
- mrt-2359 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for GLUE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GLUE
Monte Rosa Therapeutics, Inc. (GLUE) is a publicly traded biotechnology company focused on discovering and developing molecular glue degrader (MGD) therapeutics, with a pipeline of candidates targeting oncology and inflammatory diseases.
Key risk: Operating losses and deficit
BioSniper Score
Based on 4 of 6 signals
Market Cap
$1.22B
Cash Runway
—
Lead Asset
mrt-2359 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 4 clinical trials for Monte Rosa Therapeutics, Inc..
Monte Rosa Therapeutics, Inc. (GLUE) is a publicly traded biotechnology company focused on discovering and developing molecular glue degrader (MGD) therapeutics, with a pipeline of candidates targeting oncology and inflammatory diseases.
- Cash & equivalents of $90.1M as of 2026-06-30 [sec].
- Total revenue of $9.0M and net income of -$43.4M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $487.3M as of 2026-06-30 [sec].
- Accumulated deficit of $565.1M as of June 30, 2026 [sec_mda · as of 2026-08-06].
- Novartis dosed the first patient in a Phase 2 trial of MRT-6160 (DDY391) for Sjögren’s disease, triggering a $50M milestone payment to Monte Rosa [news · published 2026-09-13].
What works
- The company has a partnership with Novartis that generated a $50M milestone payment upon the first patient dosing in a Phase 2 trial of MRT-6160, indicating external validation and non-dilutive funding [news · published 2026-09-13].
- Monte Rosa anticipates its existing cash and cash equivalents and marketable securities support its cash runway into 2029, providing a multi-year operational horizon [sec_mda · as of 2026-08-06].
- The company's QuEEN™ discovery platform is designed to enable target-centric MGD discovery and development, potentially offering advantages over existing therapeutic modalities [sec_mda · as of 2025-11-06].
What to weigh
- The company has a significant accumulated deficit of $565.1M as of June 30, 2026, reflecting ongoing heavy investment in R&D without product revenue [sec_mda · as of 2026-08-06].
- Net income was -$43.4M for the period ending 2026-06-30, indicating continued operating losses [sec].
- The company's future funding requirements are uncertain and depend on many factors, including the scope, progress, and costs of clinical trials and regulatory approvals [sec_mda · as of 2026-08-06].
- Global economic or political developments could disrupt the development of product candidates [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Cash runway into 2029
“We anticipate that our existing cash and cash equivalents and marketable securities support our cash runway into 2029.”
SEC MD&A · August 6, 2026
Accumulated deficit as of June 30, 2026
“As of June 30, 2026, we had an accumulated deficit of $565.1 million”
SEC MD&A · August 6, 2026
Novartis $50M milestone payment
“Novartis (NYSE:NVS), its partner on a VAV1-targeted drug, had dosed the first patient in a Phase 2 trial of MRT-6160 (DDY391) for people with Sjögren’s disease. That single clinical checkpoint triggers a $50 million payment to Monte Rosa”
News · September 13, 2026
QuEEN™ discovery platform
“to enable our unique, target-centric, MGD discovery and development and our rational design of MGD products.”
SEC MD&A · November 6, 2025
Catalyst timeline
- 2022-10-12 · Phase 1/2 Study of Oral MRT-2359 in Patients With MYC-Driven and Other Selected Solid Tumors — This is the earliest clinical trial in the pipeline, targeting MYC-driven solid tumors.
- 2024-08-07 · Phase 1, First-in-Human Study of MRT-6160 in Healthy Subjects — This study assesses safety, tolerability, PK, and PD of MRT-6160, which later advanced to Phase 2 for Sjögren’s disease.
- 2025-06-27 · Phase 1 Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk — This study evaluates safety, tolerability, PK, and PD of MRT-8102, a NEK7 protein degrader.
- 2026-08-18 · Phase 2 Start of MRT-6160 (DDY391) for Sjögren’s disease — This milestone triggered a $50M payment from Novartis to Monte Rosa.
Risks & what to watch (3)›
Key risks
- Operating losses and deficit — Net income of -$43.4M and accumulated deficit of $565.1M as of 2026-06-30 [sec] [sec_mda · as of 2026-08-06].
- Uncertain capital requirements — Future funding depends on many factors including clinical trial costs and regulatory approvals [sec_mda · as of 2026-08-06].
- Global economic disruption — Development could be materially adversely affected by global economic or political developments [sec_mda · as of 2026-08-06].
What to watch
- Progress of the Phase 2 trial of MRT-6160 (DDY391) for Sjögren’s disease, which triggered a $50M milestone [news · published 2026-09-13].
- Data from the Phase 1 study of MRT-8102 in healthy participants and participants at cardiovascular risk with elevated CRP, which started in June 2025 [catalyst].
- Cash runway and burn rate, as the company anticipates support into 2029 but continues to report net losses [sec_mda · as of 2026-08-06] [sec].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run Monte Rosa Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Monte Rosa Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.42 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
0 buys · 20 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 20.6%
- Days to cover
- 10.8
- Shares short
- 13,398,925
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GLUE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Monte Rosa Therapeutics, Inc.?
Monte Rosa Therapeutics, Inc. (GLUE) is a publicly traded biotechnology company focused on discovering and developing molecular glue degrader (MGD) therapeutics, with a pipeline of candidates targeting oncology and inflammatory diseases.
What is Monte Rosa Therapeutics, Inc.'s lead drug candidate?
Monte Rosa Therapeutics, Inc.'s most advanced tracked candidate is mrt-2359 (Phase 2) for NSCLC; Castration-Resistant Prostate Cancer (CRPC).
Who is the CEO of Monte Rosa Therapeutics, Inc.?
Dr. Markus Warmuth M.D. is the chief executive officer of Monte Rosa Therapeutics, Inc. (GLUE).
Where is Monte Rosa Therapeutics, Inc. headquartered?
Monte Rosa Therapeutics, Inc. (GLUE) is headquartered in Boston, MA, United States.
What therapeutic areas does Monte Rosa Therapeutics, Inc. focus on?
Monte Rosa Therapeutics, Inc. develops therapies across Oncology, Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.